Vyxeos: Phase III ongoing

An independent DSMB recommended continuation without modification of an open-label, North American Phase III trial comparing 100 units/m 2 IV CPX-351 on days 1, 3 and 5 vs. 100 mg/m 2/day IV cytarabin...